Early progress on accelerating drug development with Claude

Why it matters

Anthropic's life sciences team has spent recent months embedding itself in real drug development programs, forming research partnerships with six organizations—BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group—while also launching its own drug discovery efforts, including programs for rare childhood forms of muscular dystrophy where Claude handles much of the scientific and operational work. The company frames its strategy around the observation that drug development bottlenecks are distributed across the entire process, from target identification and molecule design through manufacturing, regulatory filings, and clinical trials, rather than concentrated in a single step. The partnerships serve three stated purposes: learning where Claude's strengths and limitations lie across varied tasks, producing case studies for the wider life sciences community, and, if positive trajectories hold, directly yielding new medicines for diseases including food allergies, rare childhood diseases, and several forms of cancer. Anthropic says it has already prioritized specific model improvements based on lessons learned and plans to scale the work substantially, aiming to integrate Claude more deeply into biotechnology firms' development processes.